| scholarly article | Q13442814 |
| P2093 | author name string | W Li | |
| L Zhang | |||
| M Williams | |||
| C U Kim | |||
| D B Mendel | |||
| E J Eisenberg | |||
| M S Chen | |||
| N Bischofberger | |||
| P A Escarpe | |||
| C Sweet | |||
| K C Cundy | |||
| W Lew | |||
| K J Jakeman | |||
| J Merson | |||
| P2860 | cites work | Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding | Q24676721 |
| Characterization of temperature sensitive influenza virus mutants defective in neuraminidase | Q27865285 | ||
| Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action | Q27867721 | ||
| Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase) | Q28368367 | ||
| 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro | Q28378588 | ||
| Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection | Q28379409 | ||
| Rational design of potent sialidase-based inhibitors of influenza virus replication | Q29616647 | ||
| Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine | Q30437341 | ||
| Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza | Q30467966 | ||
| Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. | Q30471016 | ||
| The Thucydides syndrome. A new hypothesis for the cause of the plague of Athens | Q34051062 | ||
| Prodrugs. Do they have advantages in clinical practice? | Q34193849 | ||
| The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor | Q34331495 | ||
| Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity | Q34565520 | ||
| GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets | Q35120465 | ||
| Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. | Q35138108 | ||
| The molecular biology of influenza virus pathogenicity | Q39520174 | ||
| Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance | Q40777039 | ||
| Advances in influenza virus vaccine research | Q40841606 | ||
| Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor | Q41042625 | ||
| Influenza virus neuraminidase with hemagglutinin activity | Q41420817 | ||
| Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate | Q41720424 | ||
| First-pass uptake of verapamil, diazepam, and thiopental in the human lung | Q45387856 | ||
| Mucins and mucoids in relation to influenza virus action; inhibition by purified mucoid of infection and haemagglutination with the virus strain WSE. | Q45390019 | ||
| Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. | Q52595650 | ||
| Species differences in the stereoselective hydrolysis of esmolol by blood esterases | Q69922841 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 647-653 | |
| P577 | publication date | 1998-03-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. | |
| P478 | volume | 42 |
| Q34714853 | Animal Models for Influenza Virus Pathogenesis and Transmission |
| Q50111842 | Application of computational methods for anticancer drug discovery, design, and optimization |
| Q33385043 | Aurintricarboxylic acid inhibits influenza virus neuraminidase |
| Q28483824 | Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor |
| Q32038649 | Biexponential decomposition of a neuraminidase inhibitor prodrug (GS-4104) in aqueous solution |
| Q28833485 | Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue |
| Q28343667 | Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract |
| Q33813321 | Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. |
| Q34159076 | Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice |
| Q35005209 | Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir |
| Q45323679 | Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate |
| Q48113763 | Conversion and pharmacokinetics profiles of a novel pro-drug of 3-n-butylphthalide, potassium 2-(1-hydroxypentyl)-benzoate, in rats and dogs |
| Q30357472 | DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation. |
| Q28545776 | Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan |
| Q36382214 | Development of oseltamivir phosphonate congeners as anti-influenza agents |
| Q27314689 | Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets |
| Q37965570 | Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review |
| Q36785817 | Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice |
| Q41203734 | Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir |
| Q40068981 | Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction |
| Q30362700 | Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact. |
| Q92041282 | Evaluation of potential herb-drug interactions between oseltamivir and commonly used anti-influenza Chinese medicinal herbs |
| Q30395817 | Genetic and phylogenetic analyses of influenza A H1N1pdm virus in Buenos Aires, Argentina. |
| Q28349519 | In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201 |
| Q43247402 | Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue |
| Q33676271 | Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration |
| Q36845779 | Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site. |
| Q42789427 | Maximizing the value of drug stockpiles for pandemic influenza |
| Q39671211 | Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir |
| Q37337761 | Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities. |
| Q26781842 | Modeling human influenza infection in the laboratory |
| Q30356532 | Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. |
| Q35045959 | Neuraminidase inhibitors in pediatric patients: potential place in influenza therapy |
| Q30472797 | New approaches to influenza chemotherapy. Neuraminidase inhibitors |
| Q40433318 | Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release |
| Q37409972 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system |
| Q28379409 | Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection |
| Q39651456 | Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection |
| Q27317735 | Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design |
| Q28486252 | Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors |
| Q28068310 | Peramivir injection in the treatment of acute influenza: a review of the literature |
| Q28486267 | Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment |
| Q30397509 | Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant |
| Q30450742 | Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors |
| Q30360496 | Potential risks associated with the proposed widespread use of Tamiflu. |
| Q42244266 | Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: the hydrophobic side chain influences type A subtype selectivity |
| Q46138046 | Simple and sensitive spectrofluorimetric method for the determination of oseltamivir phosphate in capsules through derivatization with fluorescamine |
| Q52560078 | The expanding role of prodrugs in contemporary drug design and development. |
| Q92527298 | The inducible amphisome isolates viral hemagglutinin and defends against influenza A virus infection |
| Q27000668 | Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness |
| Q22305646 | Vaccines and antiviral drugs in pandemic preparedness |
| Q37145564 | Zanamivir oral delivery: enhanced plasma and lung bioavailability in rats |
Search more.